Kelsey C. Bertrand, MSc, MD
Department or Service
- Texas Medical Center
- Brain tumors
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Pediatric Hematology/Oncology||2020|
|University of Queensland||medical school||Doctor of Medicine||2013|
|University of Toronto/ The Hospital for Sick Children||masters||Master of Science, Laboratory Medicine and Pathobiology||2009|
|University of Guelph||other||Bachelor of Science, Biological Science||2007|
Dr. Kelsey Bertrand completed her pediatric hematology/oncology fellowship training in 2020. Prior to her fellowship training, she completed her residency at Cleveland Clinic Children’s Hospital.
Dr. Bertrand first became interested in clinical pediatric oncology when she was in graduate school studying the epigenetics of medulloblastoma, the most common malignant brain tumor in children. She hopes that research will develop more treatment options for children with difficult-to-treat brain tumors.
She is board certified by the American Board of Pediatrics.
|American Academy of Pediatrics (AAP)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Hematology (ASH)||Member|
|American Society of Pediatric Hematology/Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
Ependymoma is the third most common pediatric brain tumor. Despite decades of progress in other tumor types, there are no current cytotoxic chemotherapy or targeted agents that improve patient outcomes. My project looks to harness the power of CAR T cell therapy, while investigating epigenetic mechanisms that may affect resistance to therapy.
Dr. Bertrand’s research focuses on understanding the role epigenetics plays in high risk brain tumors, such as ependymoma and DIPG. She is trying to uncover dependencies that can be leveraged for developing therapies in the future that will improve outcomes in patients with ependymoma and DIPG.
Mack SC, Agnihotri S, Witt H, Shih DJ, Wang X, Zayne K, Barszczyk M, Ramaswamy V, Bertrand KC, Remke M, Yao Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Philips J, Gupta N, Weiss WA, Guha A,, Hawkins C, Croul S, Bader GD, Rutka JT, Zadeh G, Pfister SM, Korshunov A, Taylor MD. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res. 2015; 21(16):3750-3758.
Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, Kushida M, Head R, Clark I, Dirks P, Smith CA, Taylor MD, Rutka JT. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget. 2015; 6(25):21718-21729.
Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Transcriptional profiling of GBM invasive genes identifies effective inhibitors of the LIM kinase-cofilin pathway. Oncotarget. 2014; 5(19):9382-95.
Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis R, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, et al. Epigenetic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506(7489):445-450.
Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC. Hippocampal-sparing radiotherapy: the new standard of care for gliomas. Journal of Clinical Neuroscience. 2014; 21(1):86-90.
Mack, SC, Witt, H, Wang X, Milde, T, Yao, Y, Bertrand KC, Korshunov, A, Pfister, SM, Taylor MD. Emerging Insights into the Ependymoma Epigenome. Brain Pathology. 2013; 23(2):206-209.
Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011; 20(2):143-157.
Bertrand KC, Mack SC, Northcott PA, Garzia L, Dubuc A, Pfister SM, Rutka JT, Weiss WA, Taylor MD. PCDH10 is a candidate tumour suppressor gene in Medulloblastoma. Childs Nerv Syst. 2011; 27(8):1243-1249.
Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA Hypomethylation by Tumor Hypoxia. Epigenetics 2007; 2(2):119-125.